Cargando…

S-11-02 Regulatory considerations for non-clinical studies for COVID-19 vaccines: US FDA perspective

Detalles Bibliográficos
Autor principal:	Wrzesinski, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Scientific Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465511/ http://dx.doi.org/10.1016/j.toxlet.2022.07.101

Ejemplares similares

S-11-01 Covid19 vaccine toxicology: introduction and CRO experience/perspectives
por: Gould, S.
Publicado: (2022)

S-11-03 Accelerated timelines for non-clinical studies to support COVID-19 vaccine (AZD1222, ChAdOx1-nCov19)
por: Stebbings, R.
Publicado: (2022)

USE OF FDA-APPROVED ALZHEIMER’S DISEASE MEDICATIONS AMONG NON-INSTITUTIONALIZED U.S. ADULTS AGE 60 YEARS AND OLDER
por: Frenk, Steven, et al.
Publicado: (2019)

Stem Cell-based Products in Medicine: FDA Regulatory Considerations
por: Bauer, Steven R.
Publicado: (2004)

Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective
por: Sun, Wellington
Publicado: (2023)

USING REAL-WORLD EVIDENCE TO SUPPORT THE FDA REGULATORY APPROVAL: METHODOLOGICAL CONSIDERATIONS
por: Lu, Kevin, et al.
Publicado: (2022)

WS20.02 Input supporting a young person with increased cough suppression in the context of COVID-19
por: Shayle, A., et al.
Publicado: (2022)

First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization
por: Fortner, Andra, et al.
Publicado: (2021)

EPS1.02 The impact of COVID-19 on the prescribing practice of specialist cystic fibrosis physiotherapist non-medical prescribers in the UK
por: Brown, C., et al.
Publicado: (2021)

P05.02. Non-cognitive Therapy to Alleviate Suffering in Pediatric Palliative Care: Shamanic Journeying
por: Steinhorn, David, et al.
Publicado: (2013)

US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives
por: Wang, Shawn Shouye, et al.
Publicado: (2021)

P02.01. Bending Towards Integration: A Multiple Case Study Assessing the Progressive Landscape of Interprofessional Collaborative Care Within US Integrative Healthcare Centers
por: DeMarco, Tara
Publicado: (2013)

Staging the clinically negative neck in T1-T2 oral cancers: USgFNAC and sentinel node biopsy
por: Arya, S, et al.
Publicado: (2014)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
por: Rouse, Rodney, et al.
Publicado: (2017)

02B. Case Reports in an Evidence-based World
por: Riley, David
Publicado: (2013)

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective
por: Murphy, Ravindhi, et al.
Publicado: (2023)

02A. Design, Methods, and Outcomes for Recent Clinical Trials Utilizing Ayurvedic Medicine, Yoga, and Meditation
por: Rioux, Jennifer, et al.
Publicado: (2013)

P02.02. Quality Improvement Study Suggesting the Value of Point-of-Care Documentation of Quality of Life Vital Signs in an Academic Integrative Health Center
por: Morgan, Clinton, et al.
Publicado: (2013)

P04.02. An Integrative Approach to Fertility and Preconception Care
por: Maker-Clark, Geeta, et al.
Publicado: (2013)

AB02. UroLift: a new surgical treatment for BPH without sexual side effect
por: Wang, Run
Publicado: (2014)

RE-CONCEPTUALIZING SPOUSAL CAREGIVING FROM A DYADIC PERSPECTIVE IN THE U.S.
por: Li, Yuekang, et al.
Publicado: (2019)

FDA perspectives on potential microarray-based clinical diagnostics
por: Težak, Živana, et al.
Publicado: (2006)

P03.02. Application of an Integrative Medicine Model in Pancreatic Cancer
por: Lucius, Khara, et al.
Publicado: (2013)

The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations
por: Wittes, Janet, et al.
Publicado: (2015)

P01.02. Positive Psychology: A Path to Greater Well-being
por: Moore, Helene
Publicado: (2013)

 Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan 
por: Halioua-Haubold, Celine-Lea, et al.
Publicado: (2017)

The EVO ICL for Moderate Myopia: Results from the US FDA Clinical Trial
por: Packer, Mark
Publicado: (2022)

VARC consensus report: the FDA perspective(†)
por: Hillebrenner, Matthew G., et al.
Publicado: (2011)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

The Use of External Controls in FDA Regulatory Decision Making
por: Jahanshahi, Mahta, et al.
Publicado: (2021)

ePS1.02 Long-term psychological impact of COVID-19 on adult patients with cystic fibrosis, including transplanted patients
por: Havermans, T., et al.
Publicado: (2022)

US COVID-19 Vaccine Regulatory and Safety Practices
Publicado: (2022)

Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006–2018)
por: Seo, Yurim, et al.
Publicado: (2020)

O.4.4-11 Must we tell people to be less active to save the planet? The dilemma of physical activity promotion from a holistic health perspective
por: Gelius, Peter, et al.
Publicado: (2023)

Considerations on the clinical development of COVID-19 vaccine from trial design perspectives
por: Jiang, Zhiwei, et al.
Publicado: (2020)

Three-dimensionally fused gadolinium-enhanced and diffusion-weighted images: value in determination of multi-centricity of breast carcinoma
por: Sherif, H, et al.
Publicado: (2014)

Robot-assisted navigation system for CT-guided percutaneous lung tumour procedures: our initial experience in Hong Kong
por: Chu, CM, et al.
Publicado: (2014)

Multiparametrical diffusion weighted imaging for the detection of anaplastic transformation of low-grade gliomas
por: Freitag, MT, et al.
Publicado: (2014)

Agreement of diameter- and volume-based pulmonary nodule management in CT lung cancer screening
por: Heuvelmans, MA, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qsjdi1q7lod850m26otnl9cfbg